Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

ZYDUSLIFE NSE

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

AI Verdict: BUY Confidence: 7%

Zydus Lifesciences delivers consistent profit growth of 32% CAGR over 3 years with a stable ROE of 21%, trading at a reasonable PE of 21.8x for a healthcare compounder. With 50% of analysts rating it a Buy and strong sales momentum at 17% TTM growth, the risk-reward remains favorable.

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
1.1L Cr
Volatility
Moderate
P/E Ratio
21.98
EBITDA
₹7,530 Cr
Return on Equity
17.34%
Debt to Equity
0.09
Book Value
₹269.43
EPS
₹41.43
52W High
₹1,126
52W Low
₹835.5

Technical Indicators

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Growth Rate

Revenue Growth
13.65% ↗
Net Income Growth
13.58% ↘
Cash Flow Change
109.94% ↗
ROE
0.98% ↘
ROCE
7.64% ↘
EBITDA Margin (Avg.)
-11.29% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
BUY
Risk medium

Zydus Lifesciences delivers consistent profit growth of 32% CAGR over 3 years with a stable ROE of 21%, trading at a reasonable PE of 21.8x for a healthcare compounder. With 50% of analysts rating it a Buy and strong sales momentum at 17% TTM growth, the risk-reward remains favorable.

Bull Case 8
  • Compounded profit growth of 32% CAGR over 3 years significantly outpaces revenue growth, indicating margin expansion and operating leverage
  • Consistent ROE of 21% maintained across 3-year, 5-year, and 10-year periods demonstrates durable capital efficiency
  • TTM sales growth of 17% shows accelerating top-line momentum versus 5-year CAGR of 12%
  • PE of 21.8x is reasonable for a healthcare company delivering 18.8% profit CAGR over 5 years, implying a PEG ratio close to 1.2x
  • 50% of 30 analysts have a Buy rating, reflecting broad institutional confidence in the growth trajectory
  • Market cap of Rs 1,12,084 crore provides large-cap stability with sufficient liquidity for institutional investors
  • 10-year stock CAGR of 14% demonstrates long-term wealth creation track record through multiple market cycles
  • 5-year compounded profit growth of 19% versus sales growth of 12% indicates sustained improvement in profitability metrics
Bear Case 8
  • Dividend yield of just 0.09% is negligible, offering virtually no income support during market corrections
  • 16.67% of analysts (5 out of 30) have a Sell rating, suggesting meaningful disagreement on valuation or growth sustainability
  • Stock CAGR of only 12% over 5 years lags the 19% profit CAGR, suggesting the market has already re-rated some earnings growth
  • Price-to-book ratio of 4.13x is elevated, leaving limited margin of safety if earnings disappoint
  • TTM profit growth of 17% has decelerated from the 32% 3-year CAGR, signaling potential normalization of earnings trajectory
  • 33.33% of analysts (10 out of 30) rate it Hold, indicating the stock may be fairly valued at current levels
  • 1-year stock CAGR of 15% already prices in near-term growth, limiting upside without further earnings acceleration
  • ROE and ROCE data gaps along with unavailable debt-to-equity ratio limit full visibility into balance sheet health

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 2
  • USFDA warning letter Baddi facility May 29

    Zydus received a USFDA warning letter for its Baddi facility over purified talc not meeting USP standards. Shares fell 2.24% to ₹1,053.10 on the news, though the company says operations and supplies remain unaffected.

  • One-time losses hit EBITDA May 27

    Q4 FY26 EBITDA fell 11.4% YoY to ₹1,919 crore (margin 25.3% vs 33.2%) after adjusting for forex gains and a ₹398 crore one-time loss including a ₹397.5 crore Mirabegron litigation settlement.

Positives 5
  • Saroglitazar gets FDA Priority Review May 28

    US FDA granted Priority Review to the saroglitazar NDA for Primary Biliary Cholangitis with a PDUFA date of November 27, 2026. Phase 3 EPICS-III trial showed 56.7% biochemical response vs 9.8% placebo; US launch planned Q4 FY27.

  • $166.4M Assertio acquisition completed Jun 16

    Zydus completed the $166.4 million (₹1,590 crore) acquisition of Assertio Holdings at $23.50/share with 66.32% tender acceptance. Assertio becomes a wholly owned subsidiary focused on specialty and oncology supportive care therapies.

  • ₹1,100 crore buyback completed Jun 18

    Zydus concluded its ₹1,100 crore share buyback at ₹1,260/share (16% premium), accepting 87.30 lakh shares with 93.61x subscription. This is the company's third and largest buyback since 2022.

  • Strong Q4 FY26 revenue growth May 27

    Consolidated revenue rose 16.2% YoY to ₹7,587 crore and net profit grew 8.7% to ₹1,272.5 crore in Q4 FY26, beating street estimates. India formulations grew 14% YoY to ₹1,752.8 crore.

  • Stock up 18% YTD, outperforms benchmarks May 27

    Zydus shares have rallied 18% in 2026 and 19% over one year, significantly outperforming Nifty (-4%) and Sensex (-8%). Market cap stands near ₹1.09 lakh crore with P/E around 22x.

Neutral 2
  • Bank of America conference participation May 25

    Zydus Lifesciences participated in the Bank of America India Conference on June 2, 2026, in Mumbai for institutional investor engagement.

  • Promoter share transmission disclosed May 26

    10,000 equity shares were transmitted off-market from a deceased promoter group member to Mr. Samar Babubhai Patel, intimated to the company on May 25, 2026.

TL;DR: Zydus Lifesciences is executing well on multiple fronts — strong revenue growth (16% YoY), a completed ₹1,100 crore buyback at premium, and the strategic $166.4M Assertio acquisition expanding its US specialty portfolio. The FDA Priority Review for saroglitazar (PDUFA Nov 2026) is a major catalyst that could transition the company from generics to innovation-led. Key risks include the Baddi USFDA warning letter (though operationally contained) and one-time charges compressing margins. The overall trend is improving with clear near-term catalysts around the saroglitazar decision and US specialty revenue ramp.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
5,011
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
Expenses
3,755
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
Operating Profit
1,256
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
OPM %
25%
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
Other Income
-566
21
53
60
160
63
68
57
-139
155
75
26
-263
Interest
28
18
9
20
35
32
25
32
77
85
101
130
123
Depreciation
179
180
184
195
205
215
234
229
238
238
302
360
508
PBT
484
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
Tax %
28%
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
Net Profit
358
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
EPS in Rs
2.93
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
Other Income
45
112
127
111
183
-264
-171
2,581
-422
293
50
-7
Interest
68
53
45
91
194
342
164
127
130
81
166
439
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
EPS in Rs
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
12,799
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
52,407
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
26,639
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
1,166
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,408
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,456
17,062
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
52,407
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,777
2,117
Investing
-465
-860
-2,872
-974
-3,977
-1,012
-835
1,137
1,178
-1,492
-8,377
-8,296
Financing
-351
-935
2,316
52
1,885
-1,094
-2,549
-868
-4,400
-1,810
2,014
5,807
Net Cash Flow
178
99
756
-3
-811
399
-90
2,373
-534
-75
414
-373
Free Cash Flow
498
936
-1,623
-116
236
1,617
2,446
1,050
1,697
2,345
5,116
-530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
63
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
133
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
158
212
Working Capital Days
6
-1
-34
17
10
-19
-6
19
70
88
3
37
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Shareholding Pattern

As of Mar 2026
Promoters 75.00%
DIIs 11.20%
FIIs 6.95%
Public 5.54%
Others 1.32%
Total 100.01%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
74.88%
74.88%
74.88%
74.88%
74.88%
74.88%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.98%
74.99%
74.99%
74.99%
75.00%
75.00%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
5.72%
5.59%
7.52%
7.53%
7.32%
7.13%
7.34%
7.06%
6.95%
DIIs
11.11%
10.43%
11.22%
11.78%
12.78%
11.92%
12.94%
13.69%
13.60%
13.23%
13.09%
12.79%
12.63%
12.64%
10.65%
10.65%
11.01%
11.13%
10.86%
11.09%
11.20%
Government
0.19%
0.07%
0.07%
0.07%
0.08%
0.08%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
6.16%
7.31%
7.38%
7.40%
7.81%
8.02%
7.60%
7.04%
6.42%
5.97%
5.67%
5.60%
5.29%
5.37%
5.48%
5.47%
5.41%
5.46%
5.49%
5.54%
5.54%
Others
7.66%
7.32%
6.44%
5.87%
4.46%
5.11%
4.48%
4.29%
5.00%
5.82%
6.26%
6.63%
1.38%
1.43%
1.37%
1.36%
1.28%
1.28%
1.32%
1.31%
1.32%
No. of Shareholders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356
3,71,619
3,86,127
3,96,105
4,03,266
4,18,314

Documents

1
Concall - Mar 2017 Mar 2017
2
Concall - Sep 2017 Sep 2017
3
Concall - Nov 2017 Nov 2017
4
Concall - Jun 2018 Jun 2018
5
Concall - Jan 2019 Jan 2019

Frequently Asked Questions about Zydus Lifesciences Ltd

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise...
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ZYDUSLIFE and BSE: 532321. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of approximately ₹111138.54 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Zydus Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 21.98. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.5 and a high of ₹1,126. This range helps investors understand the stock's price volatility and recent trading levels.
Does Zydus Lifesciences Ltd pay dividends?
Yes, Zydus Lifesciences Ltd has a dividend yield of 0.09%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a Return on Equity (ROE) of 17.34%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Zydus Lifesciences Ltd on Tapetide?
On Tapetide, you can view Zydus Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 2000-04-18
Face Value ₹ 1
Issued Size 1,00,62,33,990

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List